<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01701518</url>
  </required_header>
  <id_info>
    <org_study_id>OZ123</org_study_id>
    <secondary_id>OZ123</secondary_id>
    <nct_id>NCT01701518</nct_id>
  </id_info>
  <brief_title>A Pilot Study of the Effectiveness of Intra-operative Ozurdex® in Vitrectomy Surgery for Epiretinal Membranes</brief_title>
  <official_title>A Prospective Multicentre Pilot Study of the Effectiveness of an Intra-operative Intravitreal Sustained Release Dexamethasone Implant (Ozurdex®) in Vitrectomy Surgery for Epiretinal Membranes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if an intravitreal sustained release dexamethasone implant (Ozurdex®) injected
      at the conclusion of surgery in patients undergoing vitrectomy and membrane peeling for
      idiopathic epiretinal membranes is safe and effective to decrease the macular edema, as
      demonstrated by a gain in vision and decreased in retinal thickness and volume.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We believe that the use of intravitreal corticosteroids post-operatively has the capacity to
      mitigate much of the residual swelling and retinal thickening that is seen after vitrectomy
      for epiretinal membranes. The unique pharmacokinetics of the sustained released dexamethasone
      implant (Ozurdex®) makes it an ideal delivery system to use post-vitrectomy for epiretinal
      membrane surgery. Its duration of action and its drug delivery characteristics over 6 months
      approximately match the post-operative time course of healing and remodeling in an edematous
      retina.

      This is a prospective, multicentre, pilot study evaluating the efficacy of an intravitreal
      sustained release dexamethasone implant (Ozurdex®) injected at the conclusion of surgery in
      15 patients undergoing vitrectomy and membrane peeling for idiopathic epiretinal membranes.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>3 Months</time_frame>
    <description>Best corrected visual acuity measured before surgery and 3 months after surgery using an early treatment diabetic retinopathy study (ETDRS) chart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity at 1,4 and 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Best corrected visual acuity measured at 1,4 and 6 months after surgery using an early treatment diabetic retinopathy study (ETDRS) chart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal thickness and volume</measure>
    <time_frame>6 months</time_frame>
    <description>Measure the change in retinal thickness and volume from baseline and at 1, 3, 4, 6 months using optical coherence tomography (OCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure (IOP)</measure>
    <time_frame>6 months</time_frame>
    <description>Change of IOP from baseline will be monitored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cataract progression (if applicable)</measure>
    <time_frame>6 months</time_frame>
    <description>For phakic patients, cataract progression from baseline to the 6 months visit will also be monitored.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Epiretinal Membrane</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Ozurdex</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intra-operative Ozurdex (biodegradable 0.7mg dexamethasone implant) post-vitrectomy for epiretinal membrane</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozurdex</intervention_name>
    <description>biodegradable 0.7mg dexamethasone implant</description>
    <arm_group_label>Ozurdex</arm_group_label>
    <other_name>0.7mg dexamethasone implant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing vitrectomy surgery for a visually significant (≤ 20/50) idiopathic
             epiretinal membrane.

          -  Central retinal thickness ≥ 250 μm.

          -  Age more than 18 years old.

          -  Decision makers able to give informed consent.

          -  Females of child bearing potential must agree to use acceptable means of birth control
             for the duration of the study.

        Exclusion Criteria:

          -  Secondary epiretinal membranes (ex: secondary to a retinal vein occlusion, etc.).

          -  Any other macular pathology that could affect anatomic or functional results.

          -  History of uveitis requiring intravitreal triamcinolone injection.

          -  History of steroid-responsive glaucoma.

          -  History of moderate or advanced glaucoma (cup to disc ratio ≥ 0.7).

          -  IOP &gt; 23 mm Hg if untreated, or &gt; 21 mm Hg if treated with medication.

          -  Pregnant or breast-feeding woman.

          -  Unable to attend the scheduled follow-up appointments.

          -  Patients with known hypersensitivity to any components of Ozurdex® or to other
             corticosteroids.

          -  Patients with active or suspected ocular or periocular infections including most viral
             diseases of the cornea and conjunctiva, including active epithelial herpes simplex
             keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and
             fungal diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J Kertes, MD,CM,FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlene Muller</last_name>
    <phone>416-480-5091</phone>
    <email>charlene.muller@sunnybrook.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlene Muller</last_name>
      <phone>416-480-5091</phone>
      <email>charlene.muller@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Peter J Kertes, MD,CM,FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajeev Muni, MD, FRCSC</last_name>
      <phone>(416) 867-7422</phone>
      <email>rajeev.muni@utoronto.ca</email>
    </contact>
    <investigator>
      <last_name>Rajeev Muni, MD,FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2012</study_first_submitted>
  <study_first_submitted_qc>October 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2012</study_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ozurdex</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Epiretinal membrane</keyword>
  <keyword>Macular edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Epiretinal Membrane</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

